The increasing epidemiology of diabetes and review of current treatment algorithms

Journal of the American Osteopathic Association

Volumn 110, Issue 7 SUPPL. 7, 2010, Pages

  Freeman, Jeffrey S ^a  

^a PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLYCOSYLATED HEMOGLOBIN; METFORMIN;

ALGORITHM; ARTICLE; BIOASSAY; DIET THERAPY; DISEASE MANAGEMENT; GLYCEMIC INDEX; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PREVALENCE; RISK FACTOR; UNITED STATES;

ALGORITHMS; BIOLOGICAL ASSAY; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; GLUCAGON-LIKE PEPTIDE 1; GLYCEMIC INDEX; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; RISK FACTORS; UNITED STATES;

EID: 77957239745     PISSN: 00986151     EISSN: 00986151     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet, 2007. Atlanta, GA: US Department of Health and Human Services; 2008. www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf. Accessed June 9, 2010.
2. Yokoyama H, Okudaira M, Otani T, Takaike H, Miura J, Saeki A, et al. Existence of early-onset NIDDM Japanese demonstrating severe diabetic complications. Diabetes Care. 1997;20(5):844-847.
3. American Diabetes Association. Economic costs of diabetes in the US in 2007 [published correction appears in Diabetes Care. 2008;31(6):1271]. Diabetes Care. 2008;31(3):596-615. http://care.diabetesjournals.org/content/31/3/596.long. Accessed June 9, 2010.
4. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9):1414-1431. http://care.diabetesjournals.org/content/21/9/1414.long. Accessed July 7, 2010.
5. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;127(5):1047-1053. http://care.diabetesjournals.org/content/27/5/1047.long. Accessed June 9, 2010.
6. Network of Minority Research Investigators Workshop [summary]. Bethesda, MD; April 22-23, 2004. http://nmri.niddk.nih.gov/meetingsummaries/4-22-04.pdf. Accessed June 9, 2010.
7. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003;290(14):1884-1890. http://jama.ama-assn.org/cgi/content/full/290/14/1884. Accessed July 7, 2010.
8. American Osteopathic Association. Osteopathic Medical Profession Report. Chicago, IL: American Osteopathic Association; 2009. http://www.do-online.org/pdf/2009_AOA_OMP_Report.pdf. Accessed June 9, 2010.
9. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes [published online ahead of print June 5, 2009]. Diabetes Care. 2009;32 (7):1327-1334. http://care.diabetesjournals.org /content/32/7/1327.long. Accessed June 9, 2010.
10. American Diabetes Association. Standards of medical care in diabetes-2010 [published correction appears in Diabetes Care. 2010;33(3):692]. Diabetes Care. 2010;33(Suppl 1):S11-S61.
11. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes [published online ahead of print October 22, 2008]. Diabetes Care. 2009;32(1):193-203. http://care.diabetesjournals.org/content/32/1/193.long. Accessed June 9, 2010.
12. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375(9724):1447-1456.
13. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29(12):2638-2643. http://care.diabetesjournals.org/content/29/12/2638.long. Accessed July 7, 2010.
14. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control [published correction appears in Endocr Pract. 2009;15(7):768-770]. Endocr Pract. 2009;15(6):540-559.